| Literature DB >> 27965306 |
Lea Lowenfeld1, Rosemarie Mick2, Jashodeep Datta1, Shuwen Xu1, Elizabeth Fitzpatrick1, Carla S Fisher1, Kevin R Fox3, Angela DeMichele3, Paul J Zhang4, Susan P Weinstein5, Robert E Roses1, Brian J Czerniecki6.
Abstract
Purpose: Vaccination with HER2 peptide-pulsed DC1s stimulates a HER2-specific T-cell response. This randomized trial aimed to establish safety and evaluate immune and clinical responses to vaccination via intralesional (IL), intranodal (IN), or both intralesional and intranodal (ILN) injection.Experimental Design: Fifty-four HER2pos patients [42 pure ductal carcinoma in situ (DCIS), 12 early invasive breast cancer (IBC)] were enrolled in a neoadjuvant HER2 peptide-pulsed DC1 vaccine trial. Patients were randomized to IL (n = 19), IN (n = 19), or ILN (n = 16) injection. Immune responses were measured in peripheral blood and sentinel lymph nodes by ELISPOT or in vitro sensitization assay. Pathologic response was assessed in resected surgical specimens.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27965306 DOI: 10.1158/1078-0432.CCR-16-1924
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531